Read-Gene S.A.

zł 4.88As of Sun 8 Nov 2026, 12:00 UTC
WSE:RDGHealthcare
Country Poland
PE (Fwd) •••
TSR 10Y CAGR 11.63%
Div yield —
ROE 16.15%
Biotechnology
Beta (5Y) 0.29
PE TTM 112.3
TSR TTM (18.67%)
Mkt cap zł 57.54M
ROIC 11.44%
SE Grade™
Value
Quality
Moat
Consensus
Reference
zł 6.16
26.14%
14.36%
Buy 8|6|8|0|1
4Q25
1Q26
2Q26
3Q26
Earnings per sharezł
0.06
0.06
0.07
0.07
4.81%
(0.44%)
16.35%
11.38%
Revenuezł M
5.884
5.735
5.665
5.983
12.27%
8.60%
1.68%
3.29%
Peers (US$14.53M)
Cap (US$)
PE
24.17M
—
15.80M
—
7.876M
—
Capital
TTM
5Y
10Y
Leveragex
1.359
0.027
0.027
EBIT/Intx
0.765
0.375
0.490
Own earn%
(73.98)
(9.20)
(3.29)
Sh yield%
23.93
36.59
38.51
Owners
Insiders/Inst%
1.49
62.81
Short interest%
5.53
SBC / revenue%
5.33
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
22
Op margin range%
3–8
$1 testx
−3.3
Incr. ROIC%
18